KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) FCF Margin (2016 - 2025)

Boston Scientific's FCF Margin history spans 17 years, with the latest figure at 19.17% for Q4 2025.

  • For Q4 2025, FCF Margin fell 668.0% year-over-year to 19.17%; the TTM value through Dec 2025 reached 18.22%, up 243.0%, while the annual FY2025 figure was 18.22%, 243.0% up from the prior year.
  • FCF Margin for Q4 2025 was 19.17% at Boston Scientific, down from 22.94% in the prior quarter.
  • Across five years, FCF Margin topped out at 25.85% in Q4 2024 and bottomed at 5.92% in Q1 2022.
  • The 5-year median for FCF Margin is 14.36% (2023), against an average of 12.77%.
  • The largest annual shift saw FCF Margin soared 1455bps in 2021 before it tumbled -1351bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 6.78% in 2021, then skyrocketed by 171bps to 18.35% in 2022, then increased by 1bps to 18.52% in 2023, then surged by 40bps to 25.85% in 2024, then decreased by -26bps to 19.17% in 2025.
  • Per Business Quant, the three most recent readings for BSX's FCF Margin are 19.17% (Q4 2025), 22.94% (Q3 2025), and 22.31% (Q2 2025).